Sudden Cardiac Death. Despite progress in epidemiology, clinical pro ling, and interventions, sudden cardiac death remains a major clinical and public health problem. There remain important unresolved issues that are challenges for future progress. Among these are a better understanding of the magnitude of the problem and methods of pro ling risk for individuals, the etiology and mechanisms of cardiac arrest in individuals with and without previously identi ed structural heart disease, clinical strategies for primary and secondary prevention of sudden cardiac death, and further development of community programs for improving cardiac arrest survival in the out-ofhospital environment. Each of these areas of endeavor and potential progress are reviewed and
Introduction
The second half of the twentieth century was a watershed of progress in the medical sciences. Among the successes in the various disciplines of cardiovascular medicine was the evolution of a knowledge base for understanding causes and mechanisms of sudden cardiac death (SCD) and the development of clinical strategies for intervention. Beginning with little more than a general appreciation of an association between arteriosclerotic cardiovascular disease and SCD in the middle part of the century, 1 -3 a series of cognitive and technological advances followed upon one another, leading to meaningful insights and intervention strategies by the end of the century. With the dawn of the twenty-rst century, the term "prevention of SCD" has begun to take on more than theoretical meaning.
Despite the series of successes, there still remain important unresolved issues. The limits of the progress achieved de ne the challenges that remain for the future. These can by analyzed in the context of new insights required from the underlying basic and clinical sciences, the strategies needed for further progress in prevention, and the identi cation of reasonable expectations for improving outcomes.
The challenges begin with a more precise de nition of the incidence of SCD and move to epidemiologic strategies that will predict fatal arrhythmic events more precisely. Beyond these, the development of better treatment strategies for individuals at risk must be sought, as well as more comprehensive and effective community intervention systems. New paradigms of predicting risks will have to integrate the various disciplines and interventions that may lead to reductions in the risk of SCD, combining both clinical strategies and community-based actions. Undoubtedly, progress will be incremental and cumulative; it is unrealistic to consider that a single strategic approach will have a meaningful impact on the complexities of SCD.
Epidemiology of SCD: Population and Clinical Perspectives
The magnitude of SCD as a public heath problem is self-evident, but the precise incidence remains uncertain. For more than 20 years, SCD has been stated to have an incidence of 300,000 deaths annually in the United States, with other estimates ranging from as low as 250,000 to 400,000 or more. 4 -8 This gure of 300,000 deaths accounts for an average of 1 to 2 deaths per 1,000 adults over the age of 35 per year and represents 50% of all heart-related deaths. 8 ,9 Although the 50% proportion seems to hold up from a number of sources of data, the estimate of 300,000 SCDs per year is a derived gure, based on an assumption of 600,000 cardiovascular deaths per year in the mid-1970s. Although much has changed in the population substrate and interventional capabilities in cardiovascular diseases during the past 25 years, the estimates that formed the basis for the 300,000 SCDs annually have remained unchallenged.
An example of how changing clinical and epidemiologic patterns can in uence SCD risk without being immediately apparent is shown in Figure 1 . The decrease in age-adjusted risk of coronary heart disease death from the 1940s to 1995 (Fig. 1A) has been applauded as a statement of medical and public health progress. 1 0 During the same period of time, there was a marked reduction in early mortality from acute myocardial infarction, initially thought to be related to the development of the coronary care unit and its effect on electrical and, to a more limited extent, mechanical deaths, and recently by more advanced therapies 1 1 ,1 2 (Fig. 1B) . The interaction between these two sources of data is complex. The age-adjusted risk curve expresses the fact that deaths from cardiovascular disease are occurring at older ages; it does not inherently state that the prevalence of heart disease or absolute numbers of death have changed. In addition, the short-term acute myocardial infarction mortality experience infers the establishment of a population of survivors who entered the pool of aging patients with cardiovascular disease. These factors combine with the general growth of the older population pool, because of increased birth rates during the middle part of the century. These several observations come together to suggest that, in an aging population with a lower short-term morality rate and a shifting age-adjusted risk, there is likely a growing population of patients at risk for various cardiovascular events. 1 2 The events include the development of heart failure and the risk of SCD. Finally, the 300,000 gure does not factor in the suggestion that there are now estimated to be 750,000 cardiovascular deaths annually. 1 2 In the absence of a properly designed survey that would allow a direct measure of SCD rates, the actual numerical magnitude of the risk of SCD remains speculative.
The magnitude of the risk of SCD is both age and cause related (Fig. 2) , and these two factors interact. The general assumption of a risk of 0.1% to 0.2% per year among the population aged 35 and older is an average gure for patients across that age range. Among that segment of the general population, however, the risk of SCD is strongly age related, with the most marked increase in risk between the ages of 40 to 65 years. 8 In that segment of the population, coronary artery disease is by far the most common cause of SCD (Fig. 3) , accounting for approximately 80% of all SCDs. The collective cardiomyopathies, dominated by the dilated cardiomyopathies, account for another 10% to 15%. Once coronary heart disease or cardiomyopathies are in advanced stages, they dominate and largely neutralize the agerelated component of SCD risk. Among patients with advanced structural heart disease, silent or recognized, it is the extent of disease rather than the age that determines risk; therefore, age-related risk curves tend to blunt in that subgroup of the population (Fig. 2) .
At the other end of the age spectrum, adolescents and young adults (ages 10 to 30), the order of magnitude of SCD risk is about 1/100th that of the general adult population (1 per 100,000 individuals annually), and there appears to be a modest inverse age relationship, with the adolescent group having a higher mortality risk than young adults. It is likely that the risk of lethal arrhythmia in the genetically controlled disorders tend to express more commonly in the adolescent years. 1 3 This is particularly evident for hypertrophic cardiomyopathy. 1 4 The group of disorders responsible for SCD in the adolescent and young adult group is distinctly different from those in the middle-aged to elderly group. Coronary atherosclerosis is an uncommon cause, with myocarditis, hypertrophic cardiomyopathy, long QT syndromes, right ventricular dysplasia, anomalous coronary arteries, Brugada syndrome, and idiopathic ventricular brillation (VF) accounting for the majority of these deaths. Mortality risks for any one of these diagnoses is quite variable and may, in fact, have genetic predetermination of the magnitude of risk for sudden death as an expression of the speci c mutation (see later).
The inverse relationship between the incidence of SCD and absolute numbers of events in the various epidemiologic or clinical categories is important to appreciate (Fig. 4) , particularly in relationship to the impact of therapeutic interventions. 1 5 Among the general population aged 35 years and older, the nominal incidence of 0.1% to 0.2% per year incorporates all of the estimated 300,000 sudden deaths that occur in the United States annually. With pro les of increasing risk from patients who fall into categories of high risk for development of coronary atherosclerosis, to those who have survived a coronary event, and beyond that to those with heart failure or ejection fractions , 35%, cardiac arrest survivors and the speci c high-risk postmyocardial infarction patients, the escalating risk accounts for a decreasing absolute number of events annually. The importance of recognizing this principle relates to the magnitude of population bene t for various preventative interventions. For example, the very high-risk patient categories studied in the clinical trials of implantable de brillators (Fig. 4) represent only a very small part of the universe of SCD risk, and the reported bene ts apply only to those small subgroups. This highlights the importance of nding speci c risk markers for more general segments of the population from which the potential for greater public health impact can emerge. 
Etiologic Basis of SCD and Pro ling Individual Risk
Coronary heart disease is the single most common cause of SCD in the United States and western Europe, accounting for approximately 80% of the deaths. 1 6 However, coronary heart disease is expressed as a number of different clinical syndromes, and SCD in patients with coronary heart disease must be approached from the perspective of at least ve different clinical settings and presentations. Figure 5 provides estimates of the proportion of each. Unfortunately, there is no single database that categorizes SCD expression in this way, and the estimates are approximations derived from a number of sources.
Much of the early attention to SCD risk focused on patients who had arrhythmic markers. This approach derived logically from the then-current theory of mechanisms of onset and maintenance of ventricular tachyarrhythmias. 1 7 Study groups included postmyocardial infarction patients in whom risk was suggested on the basis of chronic ambient arrhythmias, 1 8 -2 0 presumed high-risk arrhythmic markers such as inducible ventricular tachyarrhythmias, 2 1 -2 3 or patients who survived manifest lifethreatening arrhythmias, including cardiac arrest 2 4 , 2 5 (Fig. 4) . The role of the former category as a target for speci c antiarrhythmic therapy fell to the adverse outcome observations from the Cardiac Arrhythmia Suppression Trial (CAST) 2 6 ,2 7 and the Survival with Oral d-Sotalol (SWORD) Trial, 2 8 but the other two categories continued in play in clinical trials of implantable cardioverter de brillator (ICD) therapy. 2 9 -3 3 Unfortunately, risk pro ling based on laboratory inducible arrhythmias and cardiac arrest survival constitute no more than 5% to 10% of the potential universe of SCD victims 1 5 ,1 6 (Fig.  5 ). An additional category of interest, for which an important clinical trial is under way, are patients at potential risk for SCD based on the presence of left ventricular dysfunction and congestive heart failure ( Fig.  4) , in the absence of arrhythmia markers of risk. 3 4 The population category in this trial-Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)-may account for an additional 10% to 15% of potential victims among the SCD universe (Fig. 5) , an estimate based partly on projections derived from the growing prevalence of congestive heart failure. 1 2 ,3 4 Another category of risk that has been long recognized is that of cardiac arrest occurring during the onset and early evolution of acute transmural myocardial infarction or unstable angina pectoris. These categories of acute coronary syndromes contribute another 20% to the SCD incidence. 3 5 Viewing the rst three categories cumulatively and recognizing that they generate orders of magnitude of risk that are reasonable for effective intervention strategies 1 5 (with SCD-HeFT results pending), more than 50% of cardiac arrests remain in the two clinical settings that are not included among patient groups addressed in the ICD trials or acute myocardial infarction. The residual groups include patients with de ned coronary heart disease, who have a low total mortality risk because of the absence of high-risk markers for cardiac arrest or total mortality, and those victims among whom cardiac arrest is the rst and only recognized clinical manifestation of coronary artery disease (Fig. 5 ). 3 6 It is reasonable to accept the concept that speci c arrhythmic markers, in conjunction with the extent of disease, provide a well-de ned category of risk that can be bene tted by ICD therapy, 2 9 -3 3 and that SCDHeFT will either identify or put to rest the notion of preventable arrhythmic sudden death risk in a second sizeable category. There remains the need to identify risk markers for the rest of the SCD universe that will provide greater resolution of risk and, therefore, reasonable intervention applications. To achieve this goal, new approaches to risk identi cation will be required (Fig. 6 ).
In the early years of attention to risk factors for SCD, Figure 6 . the recognition of the major role played by coronary artery disease led to the use of conventional risk factors for coronary artery disease as a predictor of risk of SCD. 3 7 From a statistical viewpoint, this was reasonable because of the large proportion and numbers of SCDs that were attributable to coronary artery disease. This concept is limited, however, by the fact that these risk factors largely predict the evolution of the disease and identify orders of magnitude of risk that are too low for speci c antiarrhythmic interventions. They do not provide a speci c marker of risk for arrhythmic deaths.
Other methods for identifying the presence of structural abnormalities in coronary arteries have been suggested as potential strategies to provide greater sensitivity and speci city. For example, anatomic disease screening, with the use of electron beam computerized tomography, has been suggested as a method for large-scale screening to identify abnormal coronary arteries. 3 8 It is limited by the fact that identi cation of the structural abnormality does not identify speci c markers of arrhythmic risk. It also is limited by its inability to estimate the extent and activity of speci c lesions. Much of the progress that has been made to date in pro ling risk of SCD has been based on clinical markers that primarily identify the extent of disease, either at the myocardial or vascular level. Although resolution of overall risk is more powerful, it is still nonspeci c because of its general inability to discriminate arrhythmic death from other forms of death. To achieve better pro ling of arrhythmic risk, two approaches appear promising for the future. One is predictors of transient risk, which are intended to identify those individuals who are at risk for the transient events that trigger fatal arrhythmias 9 ,1 5 ,3 9 -4 1 (Fig. 6 ). These include pathophysiologic control mechanisms, mediated through autonomic nervous system functions such as heart rate variability 4 2 -4 4 or baroreceptor sensitivity, 4 5 measures of repolarization alterations such as T wave alternans 4 6 ,4 7 or QT dispersion, 4 8 and in ammatory markers, 4 9 -5 2 which are being evaluated as a predictor of risk for plaque destabilization, the latter being a clear marker for acute coronary syndromes. Although the in ammatory markers for plaque disruption may provide higher resolution of risk for acute coronary syndromes generally, 5 3 , 5 4 individual risk predictors, such as familial or genetic proling, might provide even greater resolution for SCD risk in speci c individuals. With regard to the latter, recent studies suggested familial clustering of cardiac arrests as a speci c clinical expression of acute coronary events 5 5 , 5 6 that might derive from a genetic predisposition.
Among the multiple pathologic and pathophysiologic studies demonstrating that coronary atherosclerotic plaque erosion or rupture correlates with acute coronary syndromes are those that demonstrate its signi cance in SCD 5 7 -5 9 (Fig. 7) . The ability to identify the individual at risk for plaque disruption, in advance of an acute coronary syndrome, might provide a powerful method for identifying individuals at potential risk of SCD. Among the factors being evaluated for this role are indices of chronic plaque in ammation. In recent retrospective studies of men 5 0 and women, 5 2 in whom both cholesterol levels and indices of in ammation could be correlated with risk of coronary events, it was observed that each appeared to provide an independent predictive value and that the combination had the strongest power of prediction of relative risk increase. High-sensitivity C-reactive protein used in the study among women 5 2 discriminated in ammatory markers of risk from cholesterol-related risk particularly well. However, because the outcomes were expressed as relative increases of a baseline risk among the subjects in the lowest terciles of cholesterol and in ammatory marker concentration, the absolute contribution of in ammatory markers (compared with cholesterol markers) remains to be determined. If the order of magnitude of absolute risk predicted by in ammatory markers is considerably higher than that of cholesterol markers, a new marker of risk with greater potential power of resolution of risk may become available. A recent observation suggesting that complex plaques may be multiple, suggesting a generalized susceptibility to plaque disruption (rather than plaque-speci c risk) and a higher recurrent event rate after myocardial infarction, 6 0 supports the notion of in ammation-based susceptibility. Other direct and indirect markers of risk of plaque destabilization from in ammatory processes also might contribute to this theory of risk prediction. 5 2 ,6 1 Familial clustering of SCD suggests a different and potentially additive bene t to risk resolution. Figure 8 summarizes data from the Paris Prospective Study on risk factors for SCD. 5 6 These data identi ed the fact that a history of parental sudden death predicted sudden death as the expression of an acute coronary event, with a nearly twofold increase in relative risk. Family history of SCD had no impact on risk of nonsudden fatal myocardial infarction. A similar observation was reported from a retrospective analysis of cardiac arrest survivors in King County, Washington. 5 5 Family clustering may result from either cultural/environmental in uences or genetic factors. Although the King County study was inconclusive in regard to this distinction, the prospective study from Paris suggested a genetic basis, because the gradient of risk increased when both parents had a family history of SCD. Recent progress in the study of the genetic syndromes that associate with sudden death risk provides a series of candidate genes (Fig. 9) , mutations, or polymorphisms that set the stage for abnormal function in the setting of acute ischemia, even if phenotypically normal at baseline. Support for the general concept of genetic variations that do not affect baseline phenotype, but do express effects during a transient event, has been emerging. 6 2 Most of the candidate genes cited control ion channel structure and function or contractile protein abnormalities, and provide initial targets for testing this general hypothesis. Other candidates may be identi ed in the future.
A hypothetical risk cascade for predicting SCD in individuals is shown in Figure 10 . It is based on the identi cation of conventional coronary heart disease risk factors, re ned by subsequent identi cation of plaque characteristics that would predispose to acute coronary syndromes and further re ned by identifying speci c individuals at risk based on arrhythmia markers, familial clustering, or genetic determinants. This risk model, subject to modi cation with emerging data, hopefully will lead to much more powerful risk resolution. The goal is to identify subgroups of patients within general populations with very high speci c risk for SCD who will be candidates for selective clinical prevention strategies.
Clinical Strategies for Preventing SCD
Early strategies for preventing SCD centered around the use of antiarrhythmic drugs, guided by either suppression of ambient ventricular arrhythmias or by the results of serial electrophysiologic studies. 6 3 These approaches were used in several categories of patients for primary or secondary prevention of SCD. It is important to recognize that the terms "primary" and "secondary," as used in SCD trials, differ from the conventional definitions of primary and secondary prevention. The former properly refers to prevention of underlying disease rather than a manifestation of the disease; any other preventative strategy in the presence of disease is considered secondary.
Before the initial clinical introduction of the ICD in 1980, antiarrhythmic drugs and surgery were the only options available. With the emergence of ICDs, their use initially was prescribed on the basis of clinical judgment, without clinical trial data available to identify bene t, and their use compared with drugs and surgery moved forward slowly. Finally, in 1996, the rst clinical trial comparing ICDs and antiarrhythmic drugs was published, 2 9 and several additional trials were published subsequently. 3 0 -3 3 The results have moved the ICD into the position of preferred therapy for speci cally de ned high-risk patients. The clinical trials of implantable debrillators have included both primary and secondary prevention strategies. Although the usage of the term "primary prevention" for ICD trials is technically incorrect, it does serve the purpose of subgrouping patients into two general categories, the study design and outcomes of which might be interpreted and applied differently.
Any study of outcomes of therapy for complex pathophysiologic disorders must take four factors into consideration ( Fig. 11): (1) relative risk reduction, (2) absolute risk reduction, (3) residual risk, and (4) cumulative bene t with other interventions. The primary endpoint reports for all clinical trials of ICD therapy, and most other large clinical trials as well, focus primarily on reduction in relative risk. 6 4 ,6 5 This is the natural consequence of the mind set of clinical trial goals, which is to identify the effect of the intervention. However, it does not quantify the effect for the individual patient. To do so requires some measure of absolute risk reduction, either the absolute numerical difference in risk observed in the test and control groups, or calculations of the number of patients needed to be treated (NNT) in order to save a life. 6 6 Other measures of impact that do not commonly receive attention include residual risk and cumulative bene t. The former refers to the absolute outcome among the treated group or test group in a clinical trial population, which identi es the component of total mortality risk that does not respond to the tested therapy. If residual risk is very high, the absolute and relative risk reduction bene ts are correspondingly limited. Cumulative bene t refers to the increment in bene t from integration of multiple interventions. This is rarely strati ed in clinical trial designs because it requires larger study populations and has never been used prospectively in any of the de brillator or antiarrhythmic trials. Post hoc subgroup analysis can be used to suggest added bene t of a secondary strategy, but this does not replace stratifying according to multiple interventions.
Comparison of the various measures of outcomes from an ICD trial, contrasted with another cardiovascular intervention, is shown in Figure 12 . The relative and absolute outcomes observed in the Antiarrhythmics Versus Implantable Device study (AVID) 3 0 at 2-year follow-up are compared with the West of Scotland Coronary Prevention Study (WOSCOPS), 6 7 a study of the impact of pravastatin (Pravachol) versus placebo in a population of men without known preexisting coronary artery disease. Although the relative risk reduction for total mortality (at 2-year follow-up in AVID and 5-year follow-up in WOSCOPS) was reasonably close (27% vs 22%), the absolute risk reduction and residual risks were very different. The absolute bene t in AVID was 7% over 2 years, whereas in the WOSCOPS, the absolute total mortality bene t was 0.9% over a study period of 5 years. In addition, the residual risk in AVID was considerably higher than in the WOSCOPS population, as might be expected for the populations in the two studies. The high residual risk in AVID dwarfs, to some extent, the absolute risk reduction.
In another comparison, ICD use versus amiodarone (AVID) and cessation of cigarette smoking among survivors of out-of-hospital cardiac arrest 6 8 both identify absolute and relative risk bene ts of the same general order of magnitude. However, these two separate observations beg the question of whether there is a positive interaction between cigarette smoking cessation and the ICD. Does the cessation of cigarette smoking identify a patient population among whom ICD bene t is even greater and residual risk lower, or does cessation of cigarette smoking account for, and neutralize, some of the apparent ICD bene t? Subgroup analyses are not suf cient to answer these questions. Cessation of cigarette smoking is but one of a number of interventions that could be tested in parallel with ICD therapy, seeking positive interactions. The general principle has been suggested for amiodarone and beta blockers in postmyocardial infarction patients. 6 9 Combined retrospective analysis of data from CAMIAT and EMIAT suggest that such a principle operates in these trials (Fig. 13 ). 7 0 ,7 1 Finally, for two major ICD trials (MADIT 2 9 and AVID 3 0 ), concern about beta-blocker imbalances in the ICD test groups has not focused on the possibility that beta blockers and ICDs provide cumulative bene t, as in EMIAT and CAMIAT. The notion of cumulative bene t is worthy of further study.
Community Programs for Cardiac Arrest Survival
Community-based approaches, targeted at reducing the incidence of SCD by improving outcomes from outof-hospital cardiac arrests, can take multiple forms. These include mass screening programs for identifying individuals at risk, public information and education programs for enhancing intervention strategies, and implementation of community-based response systems. The latter include extensions of emergency medical services and strategies using automatic external de brillators (AEDs), either through organized response systems, general public access programs, or deployment in private facilities (Fig. 14) .
The initial strategy for responding to cardiac arrest in communities engaged interested physicians with re department and paramedical personnel. The rst systems were developed simultaneously in the cities of Seattle, Washington, and Miami, Florida. The initial outcomes, measured as survival to hospital discharge, were 14% in Miami 7 2 and 11% in Seattle. 7 3 From the publication of these data in 1974 to the present, a series of changes have occurred, generating both optimistic and pessimistic data (Fig. 15) . After the initial Miami and Seattle publications, a series of advances in systems and personnel deployment 7 4 ,7 5 and encouragement of bystander cardiopulmonary resuscitation 7 6 resulted in a sharp increase in survival rates in communities with highly organized systems and committed investigators. These advances were led largely by the Seattle experience, which led to a peak survival rate in the range from 30% to 35% between the late 1970s and mid-1980s. 7 7 At the same time, it was becoming apparent that systems had to be tailored to speci c community circumstances in order to be effective. For example, early outcomes in rural communities were disappointing, compared to the Seattle and Miami data. In a study from Iowa, standard basic life support in rural areas (communities of 10,000 population or less) yielded a survival rate of only 3%. However, when those communities expanded access through ambulance-based de brillator response systems, the outcomes improved to 19%. 7 8 This was among the rst of the meaningful examples of expanded access as a method for improving survival.
Despite the encouraging data forthcoming from a number of communities, the cumulative U.S. survival rate from cardiac arrest was estimated to be in the range from 1% to 3% as recently as 1991. 7 9 This apparently resulted in part from limited rapid access to rescue systems, and in part from the fact that not all cardiac arrest victims had response systems available to them. Shortly thereafter, a major disappointment evolved from large metropolitan population centers such as New York and Chicago, in which emergency rescue systems yielded cardiac arrest survival rates of 1.4% 8 0 and 2%, 8 1 respectively. The reasons for these outcomes were likely multifactorial, including population characteristics, traf c congestion, and vertical development of communities, and resulting adverse effects on response times. More recently, overall estimates of survival outcomes from cardiac arrest are in the range of approximately 5% using conventional or enhanced response systems, 8 2 ,8 3 although there is reason for optimism based on preliminary data from police car-based and other AED programs.
There is increasing appreciation of a potential role for AEDs deployed in police vehicles, 8 4 even though comprehensive data demonstrating an incremental bene t in communities with disappointing outcomes are still lacking. 8 5 The rationale for the approach derives from the clear relationship between time to de brillation and survival. Figure 16A shows the data from the Swedish Cardiac Arrest Registry (SCAR), in which cardiac arrest due to VF among more than 2,700 victims showed a clear time relationship between time to de brillation and survival. 8 6 Even within the rst 2 minutes of cardiac arrest, survival rates were , 50%, but the major point of these data is that the survival attrition is very steep between 2 and 10 minutes, reaching approximately 10% survival at 10 minutes and continuing to decay after that.
The rationale for AED deployment is to shorten the response time and the question of whether police can effectively do this in a major city has been clari ed in part by data from Amsterdam, The Netherlands, and Miami, Florida. The Amsterdam data (ARREST) (Fig.  16B ) demonstrated a mean time bene t of approximately 5 minutes by dual response of re rescue and police in a single segment of the city of Amsterdam. 8 7 Preliminary data based on deployment of AEDs in all of the MiamiDade County, Florida, police cars has suggested a shift in the response time curve, yielding a mean police response time of 4.9 minutes from 911 call, compared with 8.1 minutes for re rescue response. 8 8 Recent data from Rochester, Minnesota, do not show a clear added bene t for overall survival by police responders compared to paramedic responders. 8 4 In that particular community, however, the differential response time between police and paramedics was , 1 minute, which would lead one to expect little difference in bene t. Viewed another way, the similar times re ecting similar outcomes support the notion that police respond- ers are effective (Fig. 17) . Accordingly, in larger communities in which traf c congestion and driving time are important variables, a potential bene t of police deployment is related to the fact that they are already on the road when a 911 call comes in. The extent to which police-based AEDs will improve survival is still unknown. In some communities, there has been concern about failure of police to respond to cardiac arrests, but the design system used in Miami-Dade County largely supersedes this problem by a tiered system for responses to conventional police calls when a medical response is in progress.
Another area in which there has been increasing attention to the potential role of AEDs is in airports and in-ight airliners. The initial published data from the Qantas Airline experience, in which airports and transPaci c airliners were equipped with AEDs in the early 1990s, suggested effectiveness in airports, but limited bene t in ight 8 9 (Fig. 18) . The ground-based responses in major airports in Australia demonstrated that 79% of the cardiac arrests were identi ed to be shockable rhythms (ventricular tachycardia [VT]/VF), and the cumulative survival rate among those victims was 21% (24% among the VT/VF subgroup). In contrast, the initial in-ight data from the Qantas program demonstrated that only 6 of 27 events were due to recognized shockable rhythms (22%), although 2 of those 6 did survive. 8 9 More disappointing was the observation that 21 (78%) of the victims had bradyarrhythmias or asystole. Among these, about half were thought to have been asleep when they were actually in cardiac arrest and were found to be asystolic when nally responded to. The other half appeared to have had primary bradyarrhythmic events, still in excess compared with ground-based experience. Subsequent data from American Airlines also demonstrated that the majority of cardiac arrests in the air were due to nonshockable rhythms, although the proportion of nonshockable rhythms was lower. 9 0 Among the victims who had shockable rhythms, there was a 38% survival rate, based on intention-to-treat analysis, yielding an overall survival rate among all mechanisms of cardiac arrest of approximately 17%. This is comparable to the better of ground-based experiences today.
The reason for the excess of bradyarrhythmic events during ight is only partially clari ed by the fact that some of the victims were thought to be sleeping. 8 9 One issue that may be operative is the relationship between arterial oxygen saturation at cruise altitudes in airliners and the propensity to, or maintenance of, VF in that environment. It is well established from aerospace data that, at a pressurized altitude of 7,000 to 9,000 feet, the partial pressure of oxygen (pO 2 ) is reduced by about 50% compared with sea level and the oxygen saturation in arterial blood is reduced as well, even among normal individuals. 9 1 Figure 19 demonstrates data from a single experience with monitoring of arterial O 2 saturation during a commercial airline ight from Miami to Chicago. During cruise, at an altitude of 37,000 feet with a cabin altitude pressure of 7,700 feet, the resting arterial oxygen saturation hovered around 90%, and with light exercise fell to approximately 85%. This is an expected response of little apparent clinical signi cance during normal cardiovascular physiology. However, it may become relevant during the onset and maintenance of cardiac arrest, because hypoxemic states tend to associate with a higher probability of bradyarrhythmic arrests or pulseless electrical activity compared to tachyarrhythmic arrests. There are some experimental data suggesting that the maintenance of VF before progressing to asystole is 89 and 90.) related to O 2 availability. 9 2 This is an area of investigation which requires further development, since it may impact on outcome expectations.
AED deployment strategies are being considered in settings beyond those described. Deployment strategies can be categorized into four categories, as demonstrated in Figure 14 . The advantages and limitations of each of the approaches are listed. The most rational approach to the determination of the validity of AED deployment strategies is based on development of scienti c support for their ef cacy and incremental bene t over conventional systems. This is best done by observations of well-controlled emergency systems initially, such as police and ambulance-based deployments, and simultaneously by extension into other public access sites in which a broader array of personnel are trained to use the devices. 9 3 These might include security personnel in public buildings, stadiums, airports, and shopping malls. Studies are under way to determine the impact of such deployments. Beyond that, AED deployment in multifamily dwellings, best controlled by de ned users such as security personnel, is used sporadically and should be scrutinized with a carefully designed registry study.
There was optimism about AED use in single-family dwellings at the time of the initial development of AEDs in the early 1980s, but this has ameliorated in part because of the growth of implantable de brillator use in higher risk patients and some of the limitations that were experienced in single-family dwelling deployments.
Expanding the Limits of Our Knowledge and Opportunities
Major expansions of our knowledge base and practical capabilities for preventing SCD will depend on a partnership among medical and nonmedical components of society. Clinical and basic science investigators and clinicians can only carry the message a limited distance and cannot themselves provide the support, tools, and research funding for making major advances. It is incumbent upon physicians interested in the problem of SCD to link closely with the media and the public to encourage awareness and action. Major steps forward will require public and political support, not just new scienti c data and opinions of the medical profession. To the extent that interested physicians are willing to extend their conventional roles into community linkages, public action, and political involvement, we will continue to observe incremental impact on the problem of SCD.
